Comparison of Sedation, Pain, and Care Provider Satisfaction Between the Use of Intranasal Ketamine Versus Intranasal Midazolam and Fentanyl During Laceration Repair
Phase: PHASE4
Conditions: Laceration of Skin
Sponsor: Corewell Health East

TITLE: Comparison of Sedation, Pain, and Care Provider 
Satisfaction between the Use of Intranasal  
Ketamine Versus Intranasal Midazolam and Fentanyl during 
Laceration Repair 
NCT03528512 
11/21/2018 

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 1 of 19 
Version #   11/15/18 
 
 
 
 
 
TITLE: Comparison of Sedation, Pain, and Care Provider Satisfaction between the Use of 
Intranasal Ketamine Versus Intranasal Midazolam and Fentanyl during Laceration Repair 
 
 
 
 
 
1. Study Overview 
 
 
Children frequently present to pediatric emergency center (PEC) with lacerations. Often, 
laceration repair proves to be traumatic for the children and the parents alike. Ideally, laceration 
repair should be as painless and free from anxiety as possible. To work towards this goal, 
different analgesic and sedative management strategies use intravenous, intramuscular and, 
more recently, intranasal routes. 
Unfortunately, intravenous access is hard to establish and may be painful for the child. 
The intramuscular route is often similarly painful. Due to the rich blood supply and large surface 
area of the nasal vestibule, intranasally (IN) administered medications are highly absorbed. IN 
approaches for procedural pain reduction, such as during dental work, have been demonstrated 
to make drug administration painless and well tolerated, making it an attractive potential 
alternative to commonly used intravenous and intramuscular approaches. 
In several small research studies, high doses of intranasal ketamine (9 mg/kg) produce 
adequate sedation during laceration repair with minimal side effects. A recent study compared 
IN ketamine, midazolam, fentanyl or combination of these drugs for pain 
management and urgent analgesia sedation, and demonstrated that they are effective and safe, 
reporting that ~60% of study participants sustained mild to moderate sedation. 
Unfortunately, there are not enough studies done to evaluate the sedation effect of IN 
ketamine for laceration repair. Small studies (Tsze, DS and Nemeth, M) showed that IN 
ketamine is an effective alternative but no studies are done to compare combination IN 
midazolam and fentanyl to IN ketamine. Our null hypothesis is that there is no difference in 
sedation scores during laceration repair when comparing use of IN ketamine to IN midazolam 
and IN fentanyl. 
We will recruit a total of 30 pediatric patients (6 months – 10 y age) in a randomized 
double-blinded pilot study of IN ketamine alone or combined IN midazolam and IN fentanyl for 
laceration repair, comparing levels of pain and sedation scores using validated pediatric metrics 
as the primary outcomes. In addition, we will assess comparative nurse and physician 
satisfaction in each of these two groups. Understanding the relative effectiveness of these two 
approaches will help us identify a safe, effective, and easily administrable method to manage 
pain and anxiety, thereby, improving patient experience and outcomes during the often 
traumatic laceration repair procedure. 
 
 
2. Study Objectives 
 
 
Primary objectives: 
1.  The primary outcome variable is the maximum sedation score as measured by the 
University of Michigan Sedation Scale. This scale consists of an ordinal scale from 0 to 4.

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 2 of 19 
Version #   11/15/18 
 
 
 
 
 
 
2.  The proportion of children who receive a maximum sedation score of either 1 or 2 (without 
distinguishing between those values) between the two sedation groups 
(IN ketamine versus IN midazolam + IN fentanyl) will be compared. 
 
 
Secondary (or specific) objectives: 
 
The effect of IN ketamine vs IN midazolam + IN fentanyl on pain scores during laceration 
repair will be compared between the two groups 
    Nurse and physician satisfaction will be compared between the two groups 
    Any adverse events will be compared between the two groups. 
 
Rates of failure to repair laceration due to agitation or intolerable pain with switch to 
intravenous medications will be compared between two groups 
 
Any significant change in vitals during analgosedation (any desaturation - spO2 < 90, 
and hypotension per age-related norms) will be compared between the two groups. 
 
3. Methodology 
 
 
Study Design: 
We will conduct a pilot study as a randomized double blinded clinical fashion between March 
2018 - March 2019 in the Pediatric Emergency Center at Beaumont Children’s Hospital, a 
tertiary pediatric hospital in Royal Oak, MI. Parents of children who meet study inclusion criteria 
and none of the exclusion criteria will be approached and consented by the physician prior to 
randomization (consent form attached). Verbal assent will be obtained for children 7-10 years of 
age. 
 
Randomization: 
A randomization list created by an online randomization tool* will be used to assign participants 
to a treatment arm (in random blocks of 4, 6, and 8).  As participants are enrolled into the study, 
they will be assigned to the next available sequential treatment arm. 
 
* Sealed Envelope Ltd. 2017. Create a blocked randomization list. [Online] Available from: 
https://www.sealedenvelope.com/simple-randomiser/v1/lists [Accessed 10 Jan 2018]. 
 
 
Once the treatment arm has been determined, two syringes of medication will be prepared. 
One syringe will contain either midazolam (for those assigned to the midazolam + fentanyl arm) 
or ketamine (for those assigned to the ketamine arm). The other syringe will contain either 
fentanyl (for those assigned to the midazolam + fentanyl arm) or 0.9% sodium chloride (for 
those assigned to the ketamine arm). 
 
Syringes for each treatment assignment will be visually identical in appearance.  The volume of 
each syringe will depend on weight-based dosing of the study medication.  Each treatment arm

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 3 of 19 
Version #   11/15/18 
 
 
 
 
 
will have the same volumes of medications so it will be indistinguishable between treatment 
arms. 
 
For example, if a participant weighs 30 kg and is assigned to the midazolam + fentanyl arm, one 
syringe will contain midazolam (9 mg/1.8 mL) and the other syringe will contain fentanyl (45 
mcg/0.9 mL). If the same participant was assigned to the ketamine arm, one syringe will 
contain ketamine (90 mg/1.8 mL) and the other syringe will contain 0.9% sodium chloride (0.9 
mL). 
 
Medication Concentrations: 
Midazolam 5mg/mL 
Fentanyl 50 mcg/mL 
Ketamine 50 mg/mL 
Sodium chloride 9mg/mL 
 
Explanation of Activities: 
 
 
 
Eligibility criteria screening will be done by the fellow or attending physician during the 
shift. 
 
Participants who met inclusion criteria and none of the exclusion criteria will be 
approached and consented by the physician prior to randomization (consent form 
attached). 
    Verbal assent will be obtained for children 7-10 years of age. 
 
XAP (topical anesthetic - lidocaine-epinephrine-tetracaine topical solution) will be applied 
to all lacerations for 20 minutes duration before giving the intranasal medications 
 
Participants will be randomized to one of two groups: 
 
 
Group 1: Intranasal ketamine 3mg/kg (max 100 mg) + saline 0.03 ml/kg (max 2ml) 
Group 2: Intranasal midazolam 0.3 mg/kg (max 10 mg) + fentanyl 1.5mcg/kg (max 100 mcg) 
The EC pharmacist will prepare syringes dependent on group assignment by consecutively 
numbered envelopes, and will be provided to a nurse who will be blinded by these assignments. 
These drugs will be delivered to the participant via two MAD (mucosal atomization) devices for 
intranasal application of medications prior to laceration repair. 
 
Intranasal Administration of Study Medications: 
 
For this study, intranasal medications will be administered via an intranasal MAD device 
to maximize the surface area for absorption.

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 4 of 19 
Version #   11/15/18 
 
 
 
 
 
 
The participant will be positioned sitting at 45 degrees, or lying supine with head turned 
to one side, and the atomizer (MAD device) will be applied to the nostril (pointing slightly 
up and outward) 
 
If the syringe fluid volume is larger than 1ml, then ½ of the volume will be delivered to 
each nostril. The same process will occur for the second medication. 
 
After the intranasal application of the medications, the physician will wait for 10 min 
before starting the laceration repair. 
 
Laceration Repair: 
    Laceration will be repaired by the resident, fellow or attending working in PEC. 
 
Vitals (heart rate, respiratory rate, oxygen saturation and blood pressure) and baseline 
pain score will be recorded prior to intranasal medication administration. 
 
When the nurse records the first set of vitals before giving the medications they will also 
complete a form which includes vital signs, sedation score, pain score and will repeat 
every 5 minutes until 10 minutes after the laceration repair or until the patient is awake. 
 
The nurse will fill out a form that includes vitals (heart rate, respiratory rate, oxygen 
saturation and blood pressure), sedation score, pain score immediately prior to applying 
IN medications and repeat every 5 minutes until the end of the laceration repair, and five 
minutes after the end of the procedure or until the patient is able to follow commands. 
Any adverse events (e.g. nausea, vomiting, epistaxis, dizziness) will be recorded on the 
nurse’s form. 
 
Once the procedure has been completed, the satisfaction questionnaire will be filled out by the 
nurse and physician who were at bedside during the procedure. (Questionnaire attached below) 
All process will be videotaped and two consistent scorers who are blinded to the medications, 
will watch all the videos in the end of the study and will fill the questionnaire to prevent interrater 
reliability as a limitation to the study. 
 
 
 
Pain Scores: 
    6 months of age to < 4 years of age, FLACC pain scale will be used for pain evaluation. 
    ≥ 4 to 10 years of age FACES pain scale will be used for pain evaluation. 
FLACC pain scale;

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 5 of 19 
Version #   11/15/18 
 
 
 
 
 
 
 
 
 
FACES pain scale 

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 6 of 19 
Version #   11/15/18 
 
 
 
 
 
Sedation Score: 
 
 
 
Hypotension (age-related criteria): 
Infants, 6 months to 12 months: Systolic Blood Pressure <70 mmHg 
Children 1 to 10 years: Systolic Blood Pressure <70 + (age in years x 2) mmHg 
Children >10 years: Systolic Blood Pressure <90 mmHg 
 
 
 
 
 
4. Data collection: 
    Age, Sex, Weight 
    The site of the laceration and number of sutures placed 
    Past medical history – e.g. history of autism or behavior issues (if documented) 
    Baseline pain scores and mean pain score during the laceration repair, and scale used 
 
Mean sedation score during the laceration repair, also sedation scores at every 5 
minutes interval before, during and after the procedure 
    Nurse, physician satisfaction questionnaire 
 
Adverse events (nausea, vomiting, epistaxis, dizziness, etc) and significant change in 
vitals (desaturation, hypotension) 
 
Total length of stay in the PEC, and length of stay from the intranasal medication 
administration to the discharge from the PEC. 
 
 
5. Risks and Benefits 
 
 
Risk assessment:

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 7 of 19 
Version #   11/15/18 
 
 
 
 
 
Patients will be monitored continuously starting immediately before administration of the drugs 
until the patient is awake, able to follow instructions and can drink. Respiratory rate, heart rate 
and oxygen saturation will be monitored continuously and blood pressure will be monitored 
every 5 minutes. 
 
Study Risks: 
Intranasal midazolam: 
Most frequent (>10%) 
    Burning sensation in the nose while drug administration 
    Unpleasant taste 
    Salivation 
    Nausea 
 
 
Less frequent (1-10%) 
    Vomiting 
 
 
Rare (<1%) 
    Low Blood Pressure 
    Allergic Reaction 
 
 
Intranasal fentanyl: 
Most frequent (>10%) 
    Burning sensation in the nose while drug administration 
    Unpleasant taste 
 
 
Rare (<1%) 
    Nose bleeding 
    Allergic Reaction 
 
 
Intranasal ketamine: 
Most frequent (>10%) 
    Nausea 
    Salivation 
 
 
Less frequent (1-10%) 
    Vomiting 
    Dizziness 
 
 
Rare (<1%) 
    Difficulty breathing 
    Brief low oxygen saturation

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 8 of 19 
Version #   11/15/18 
 
 
 
 
 
 
Benefits: 
The patient will be more comfortable and experience less pain during the procedure with 
minimal recall of the procedure afterwards, but this cannot be guaranteed. Information gained 
from the results of this study may be of benefit to other children in the future who undergo 
similar procedures. 
 
6. Eligibility Criteria: 
Inclusion Criteria 
●   Pediatric patients 6 months to 10 years who required laceration repair in the pediatric 
emergency center. 
● Laceration should be less than 5 cm long, require 2 or more sutures and no consult 
supspeciality consult for repair. 
● XAP (topical anesthetic - lidocaine-epinephrine-tetracaine topical solution) will be applied 
to all lacerations for 20 minutes duration before giving the intranasal medications. 
 
Exclusion Criteria 
●   Age < 6 months 
●    Documented allergy or adverse effect to ketamine, midazolam or fentanyl 
●    Epistaxis 
●    Partial upper airway obstruction 
●    Oxygen requirement via nasal cannula 
●   Acute mental status changes (e.g. obtunded or somnolent) 
●   Documented increased intracranial pressure or increased ocular pressure 
●   Documented porphyria 
●   Previously involved in the study 
●   Parent or patient refusal 
●   Acutely compromised vitals (hypotension,  desaturations, respiratory distress) 
●   Any known heart disease 
●   If any previous opioid use for analgesia during the visit 
●   Need for staples 
●   Scalp wounds 
●   General trauma requiring additional sedation 
● Patients who received pain medications before laceration repair (acetaminophen or 
ibuprofen use) 
 
7. Data Analysis: 
Our primary goal with the pilot study is to determine if there is any difference between IN 
ketamine versus IN midazolam and IN fentanyl on sedation scores during laceration repair. 
Mean sedation scores during laceration repair will be filled by the nurse, physician and 2 
consistent scorers in the questionnaire. Two consistent scorers will be chosen from EC or 
pediatric attendings who are not enrolled any patient to the study. In the end of the study, they

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 9 of 19 
Version #   11/15/18 
 
 
 
 
 
will be asked to watch the videos and fill the questionnaire. Kappa coefficient (κ) will be 
measured which measures the inter-rater agreement for qualitative items. 
The analysis strategy for the primary outcome will be a test of equal probabilities of maximum 
sedation scores of 1 or 2 for the two schemes, along with a 95% confidence interval for the odds 
ratio relating the proportion of 1’s or 2’s for the two medication schemes. After our pilot study, 
we will evaluate the effect of IN ketamine in comparison to IN midazolam and IN fentanyl, as 
well as, evaluate potential adverse effects. If results are significant, we will conduct a 
randomized double blinded controlled trial with the goal of 162 patients in total with calculated 
study power of 0.8. 
 
 
 
8. Data Safety Monitoring Plan: 
IN ketamine, midazolam and fentanyl are safe medications that are FDA approved for use in 
pediatric emergencies. Dr. Graham Krasan will participate as the Medical Monitor and will 
review the study every quarter for eligibility criteria of enrolled participants, serious adverse 
events, drop outs, and potential difficulties in recruiting children to the study. He will oversee the 
progress of the trial and to ensure that the study is conducted and data are handled in 
accordance with the protocol, Good Clinical Practice, and applicable ethical and regulatory 
requirements. He will be responsible for controlling adherence to the protocol, ensuring that 
data are correctly and completely recorded and reported, and confirming that informed consent 
is being obtained and recorded for all subjects prior to their participation in the trial. 
 
9. Existing Study Data 
 
 
Nemeth, M developed a protocol for INA (intranasal analgesia) for acute pain therapy and 
urgent analgesia and/or sedation and assess the level of pain, sedation and reactivity score. 
The study team found that fentanyl was the most frequently used drug for acute pain therapy. 
S-ketamine/midazolam was the most frequent combination for urgent analgesia and/or sedation. 
They showed that intranasal fentanyl, s-ketamine, and midazolam was effective and safe for a 
broad range of indications in pediatric acute care and failure rate was low with only 5% of the 
pediatric patients needing conversion to IV. It was a non-blinded and non randomised study and 
drug choice made by attending pediatric anesthesiologist. In our population sedation is applied 
mostly by pediatric emergency attendings and randomised comparison of different intranasal 
administration can guide us to use most efficient medication. Nemeth,M used fentanyl 2 ug/kg of 
fentanyl, 4mg/kg of s-ketamine and 0.5mg/kg of midazolam in the study. 
 
Weber, F conducted a prospective randomized double-blind clinical trial to evaluate the effect of 
intranasal s-ketamine and midazolam for induction of anesthesia to preschool children. They 
found that intranasal administration of s-ketamine and midazolam provides good conditions for 
induction of anesthesia without evidence of serious adverse effects. Compares midazolam 0.2 
mg/kg with s-ketamine 1 mg/kg, midazolam 0.2mg/kg with s-ketamine 2mg/kg and midazolam 
0/2mg/kg alone. Sedation scores improve significantly with both ketamine groups. This study is 
done to evaluate induction and parental separation and there was no painful procedures, so the

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 10 of 19 
Version #   11/15/18 
 
 
 
 
 
effects evaluated mostly for anxiolysis. Dose for ketamine is low for analgosedation which 
usually suggested 3 - 6mg/kg. 
 
Del Pizzo, J wrote a review of intranasal medications for sedation. Del Pizzo,J cited study of 
Theroux et al that intranasal midazolam at 0.4 mg/kg reduced cry and struggle scores of 
preschool children requiring laceration repair. Adverse effects of intranasal midazolam reported 
as nasal irritation, unpleasant taste, salivation, nausea and vomiting, change in vision, and gait 
difficulties. 
Fentanyl is an ideal intranasal medication because of its high lipophilicity and relatively 
low molecular weight. Peak plasma concentration is reached in 10 to 15 minutes and Del Pizzo 
cited study of Borland et al that 1.7 mcg/kg of intranasal fentanyl had comparable analgesia to 
0.1 mg/kg of intravenous morphine for long-bone fractures in children. Adverse effects are rare 
and include epistaxis, unpleasant taste, and nasal irritation. 
Ketamine is often used in the pediatric population as a potent analgesic and sedative. It 
has recently been the focus of study for intranasal administration and Del Pizzo cited a trial by 
Roelofse and colleagues that compares the intranasal administration of 20 mcg sufentanil and 
0.3 mg/kg midazolam to 5 mg/kg ketamine and 0.3 mg/kg midazolam in healthy children 
undergoing dental surgery and found that both groups were equally sedated and received the 
general anesthesia mask well. All three medications were effective for procedural sedation. 
 
Tsze DS conducted a randomized, prospective, double-blind trial of children who required 
sedation for laceration repair. Participants with simple lacerations were randomized by age to 
receive 3, 6, or 9 mg/kg intranasal ketamine. Of the 12 participants enrolled, 3 children achieved 
adequate sedation, all at the 9 mg/kg dose. Both the 3 mg/kg and 6 mg/kg doses were not 
evaluated further due to their lack of efficacy. The only adverse event documented in this study 
was vomiting in 1 patient. Of note, this study compared different doses of intranasal ketamine. 
Due to the low number of participants enrolled the study was suspended early and data is not 
reliable. Our goal is to use ketamine 3 mg/kg intranasally, which in other pediatric studies was 
sufficient to produce mild sedation. 
 
Lane RD studied the effect of atomized intranasal midazolam for minor procedures in 
the pediatric emergency department. Lane, RD performed a retrospective chart review of 
children who received intranasal midazolam sedation. Initial IN midazolam dose was 0.4 mg/kg 
(range, 0.3-0.8 mg/kg). Laceration repair was the most common procedure necessitating 
sedation (89%). Showed that median degree-of-sedation was anxiolysis without any adverse 
events. This study shows that 0.4mg/kg of midazolam is effective for anxiolysis. In our study we 
will use 0.5 mg/kg as mentioned by Nemeth,M. We will compare the known effect of midazolam 
to ketamine for non-inferiority. 
 
Andolfatto G assessed the analgesic effect of intranasal ketamine in the emergency 
department with doses of 0.5 to 0.75 mg/kg of intranasal ketamine. No serious adverse effects 
occurred. Minor adverse effects included dizziness, feeling of unreality, nausea, mood change 
and changes in hearing. All adverse effects were transient and none required intervention.

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 11 of 19 
Version #   11/15/18 
 
 
 
 
 
There were no changes in vital signs requiring clinical intervention. Intranasal ketamine reduced 
pain scores to a clinically significant degree in 88% of ED patients in this study. We will study 
high dose of intranasal ketamine for analgosedation in our study. 
 
Graudins A conducted the PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a 
randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate 
to severe pain in children with limb injuries. 
Graudins conducted a double-blind, randomized, controlled trial comparing fentanyl at 1.5 
mg/kg with ketamine at 1 mg/kg in children aged 3 to 13 years with isolated limb injury and pain 
of more than 6 of 10 at triage. In the study it was found that intranasal fentanyl and ketamine 
were associated with similar pain reduction and ketamine with more minor adverse events. 
This study is another study only done for the purpose of pain reduction with no procedures. 
 
 
Louon A checked the effect of nasal midazolam and ketamine for pediatric sedation during CT. 
In this study, a mixture of midazolam (0.56 mg/kg) and ketamine (5 mg/kg) administered nasally 
Louon A observed that the combination was effective in 83% of the cases and there was no 
complications. There was no respiratory depression and oxygen desaturation, suggestive that 
this combination is safe and efficient in the CT room. (30 children). We will use the similar doses 
in our study and it is good to see that there was no complications. 
 
Abrams R evaluated the safety and effectiveness of intranasal administration of sedative 
medications (ketamine, midazolam, or sufentanil) for urgent brief pediatric dental procedures. 
In this study they used ketamine 3 mg/kg; midazolam 0.4 mg/kg; or sufentanil 1.5 or 1.0 mcg/kg- 
intranasally in a randomized, double-blinded protocol. The sedation scores for midazolam and 
ketamine were both 4. 2 children in ketamine group had brief desaturations. 
They also compared the effect of Sufentanil 1.5 mcg/kg and 1.0 mcg/kg. The 1.5 mcg/kg 
dose caused significant desaturations and 1 mcg/kg dose no desaturations. In their conclusion, 
the investigators mentioned that midazolam and ketamine are acceptable and ideal for urgent 
brief pediatric dental procedures. 
Our study will be similar to the Abrams study with the difference of using ketamine, and 
midazolam with fentanyl om combination. Our study will employ these medications for laceration 
repair. 
 
Green SM, Roback MG, Kennedy RM, Krauss B wrote an updated guideline for 
emergency department ketamine dissociative sedation in 2011. 
They mentioned that ketamine dissociation appears at a dosing of approximately 1.0 to 1.5 
mg/kg intravenously (IV) or 3 to 4 mg/kg intramuscularly (IM). 
Once the dissociative threshold is reached, administration of additional ketamine does 
not enhance or deepen sedation, as would be the case with opioids, sedative-hypnotics, or 
inhalational agent, American College of Emergency Physicians: “A trancelike cataleptic state 
characterized by profound analgesia and amnesia, with retention of protective airway reflexes, 
spontaneous respirations, and cardiopulmonary stability,” ie, dissociative sedation.

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 12 of 19 
Version #   11/15/18 
 
 
 
 
 
The literature is strongly supportive of the safety and efficacy of ED dissociative sedation for a 
variety of brief painful or emotionally disturbing procedures in both children and adults. 
In their update, they mention that it is safe to use ketamine in infants younger than 12 months, 
but not in infants younger than 3 months of age due to reported cases of airway complications 
including airway obstruction, laryngospasm, and apnea. Ketamine has been shown to 
exacerbate schizophrenia. They also recommend that ketamine should be avoided in children 
with known or possible coronary artery disease, congestive heart failure, or hypertension due to 
inhibition of the reuptake of catecholamines, and the resulting sympathomimetic effect. 
In our study, we will exclude infants younger than 3 months and children with known 
heart disease. We will also exclude children older than 10 years of age because they mostly 
tolerate laceration repair with only local anesthesia and usually does not require sedation. 
 
10. References 
1.  Nemeth M, Jacobsen N, Bantel C, Fieler M, Sümpelmann R, Eich C. Intranasal 
Analgesia and Sedation in Pediatric Emergency Care-A Prospective Observational 
Study on the Implementation of an Institutional Protocol in a Tertiary Children's 
Hospital. Pediatr Emerg Care. 2017 Jan 24. doi: 10.1097/PEC.0000000000001017. 
[Epub ahead of print] PubMed PMID: 28121974. 
2.  Weber F, Wulf H, el Saeidi G. Premedication with nasal s-ketamine and 
midazolam provides good conditions for induction of anesthesia in preschool 
children. Can J Anaesth. 2003 May;50(5):470-5. PubMed PMID: 12734155. 
3.  Del Pizzo J, Callahan JM. Intranasal medications in pediatric emergency 
medicine. Pediatr Emerg Care. 2014 Jul;30(7):496-501; quiz 502-4. doi: 
10.1097/PEC.0000000000000171. Review. PubMed PMID: 24987995. 
4.  Tsze DS, Steele DW, Machan JT, Akhlaghi F, Linakis JG. Intranasal ketamine for 
procedural sedation in pediatric laceration repair: a preliminary report. Pediatr 
Emerg Care. 2012 Aug;28(8):767-70. PubMed PMID: 22858745 
5.  Lane RD, Schunk JE. Atomized intranasal midazolam use for minor procedures in 
the pediatric emergency department. Pediatr Emerg Care. 2008 May;24(5):300-3. 
doi: 10.1097/PEC.0b013e31816ecb6f. PubMed PMID: 18496113 
6.  Andolfatto G, Willman E, Joo D, Miller P, Wong WB, Koehn M, Dobson R, Angus E, 
Moadebi S. Intranasal ketamine for analgesia in the emergency department: a 
prospective observational series. Acad Emerg Med. 2013 Oct;20(10):1050-4. doi: 
10.1111/acem.12229. PubMed PMID: 24127709. 
7.  Graudins A, Meek R, Egerton-Warburton D, Oakley E, Seith R. The PICHFORK (Pain 
in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing 
intranasal ketamine and fentanyl for the relief of moderate to severe pain in 
children with limb injuries. Ann Emerg Med. 2015 Mar;65(3):248-254.e1. doi: 
10.1016/j.annemergmed.2014.09.024. PubMed PMID: 25447557. 
8.  Louon A, Reddy VG. Nasal midazolam and ketamine for paediatric sedation during 
computerised tomography. Acta Anaesthesiol Scand. 1994 Apr;38(3):259-61. PubMed 
PMID: 8023666.

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 13 of 19 
Version #   11/15/18 
 
 
 
 
 
9.   Abrams R, Morrison JE, Villasenor A, Hencmann D, Da Fonseca M, Mueller W. 
Safety and effectiveness of intranasal administration of sedative medications 
(ketamine, midazolam, or sufentanil) for urgent brief pediatric dental 
procedures. Anesth Prog. 1993;40(3):63-6. PubMed PMID: 7645790; PubMed Central 
PMCID: PMC2148744. 
10. Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for 
emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med. 
2011 May;57(5):449-61. doi: 10.1016/j.annemergmed.2010.11.030. PubMed PMID: 
21256625. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Attached documents: 
Satisfaction Questionnaire 
Nursing Sheet 
Screening and Eligibility Criteria 
Data collection tool 
Schedule of events 
Budget Estimate 
Consent Form 
 
Nurse/Doctor Questionnaire: 
1- Any difficulties administering the intranasal medications? (only nurse) 
Yes, please explain 
No 
In your opinion, please rate. 
2- Patient had tolerable pain during the procedure. 
1-Strongly disagree 
2-Disagree 
3-Neutral 
4-Agree 
5-Strongly agree 
3- Patient was adequately sedated/ calm for the procedure? 
1-Strongly disagree 
2-Disagree 
3-Neutral 
4-Agree

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 14 of 19 
Version #   11/15/18 
 
 
 
 
 
5-Strongly agree 
4- Patient tolerated the procedure well? 
1-Strongly disagree 
2-Disagree 
3-Neutral 
4-Agree 
5-Strongly agree 
5- Would you recommend this process if there was a need to repeat the same procedure? 
Yes 
No 
6- How do you rate overall experience for this procedural sedation ? 
Poor 
Fair 
Good 
Very good 
Excellent 
 
 
7. Physician Name 
 
 
Nursing Sheet 
 
 
MRN: 
Age: 
Sex: 
Race: 
Time of IN administration: 
Time of starting laceration repair: 
Time of ending the procedure: 
Time of discharge: 
If procedure is longer than 30 min, please continue recording the vitals, sedation and pain score 
 
 
 
Vital 
signs 
Prior to IN 
medication 
5 
min 
10 
min 
15 
min 
20 
min 
25 
min 
30 
min 
Time 
HR 
BP 

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 15 of 19 
Version #   11/15/18 
 
 
 
 
 
RR 
pO2 
Sedation 
score 
Pain 
Score 
 
 
 
Adverse events: 
    Nausea                                                          Yes                             No 
    Vomiting                                                        Yes                             No 
    Epistaxis                                                        Yes                             No 
    Irritation during IN administration                  Yes                             No 
    Desaturations                                                Yes                             No 
    If patient required any intervention, please specify 
o Tactile stimulation 
o Oxygen support 
o Bag-valve mask 
o Intubation 
o Other             _ 
    Hypotension that required intravenous fluid  Yes                             No 
    Stridor, difficulty breathing, laryngospasm    Yes                             No 
    Allergic reaction                                             Yes                             No 
(Rash, difficulty breathing, tongue swelling) 
    Procedure failure requiring other meds         Yes                             No 
o Other             _ 
 
 
 
Screening and Eligibility Criteria: 
Inclusion Criteria 
● Pediatric patients 6 months to 10 years who required laceration repair in the pediatric 
emergency center. 
●   Laceration less than 5 cm long, require more than 2 sutures, and no consult for repair. 
● XAP (topical anesthetic - lidocaine-epinephrine-tetracaine topical solution) needs to be 
applied for all lacerations for 20 minutes duration before giving intranasal medications. 
 
Exclusion Criteria 
●   Age < 6 months

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 16 of 19 
Version #   11/15/18 
 
 
 
 
 
●   Documented allergy or adverse effect to ketamine, midazolam, or fentanyl 
●   Epistaxis 
●   Partial upper airway obstruction 
●   Oxygen requirement via nasal cannula 
●   Acute mental status changes (e.g. obtunded or somnolent) 
●   Increased intracranial pressure or increased ocular pressure 
●   Porphyria 
●   Previously involved in the study 
●   Parent or patient refusal 
●   Acutely compromised vitals (hypotension, low saturations, respiratory distress) 
●   Any known heart disease 
●   If any previous opioid use for analgesia during the visit 
●   Need for staples 
●   Scalp wounds 
●   General trauma requiring additional sedation 
●   Patients who received pain medications before laceration repair 
 
 
 
Data Collection Tool 
Patient Number 
MRN 
Age 
Sex 
Race 
Time between IN administration to start laceration repair 
Time between IN administration to end of the procedure 
Time between IN administration to discharge 
Any Bradycardia (HR<60) 
Any Hypotension 
Any apnea 
Any significant change in pO2 (<90%) 
Max sedation score during the procedure 
Mean pain score during the procedure 
Nause 
Vomiting 
Epistaxis 
Nasal irritation 
Desaturations 
Hypotension 
Intervention for desaturation 
Stridor, difficulty breathing, laryngospasm 
Allergic reaction 
Failure

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 17 of 19 
Version #   11/15/18 
 
 
 
 
 
Other adverse events 
Survey Nurse Q1 
Survey Nurse Q2 
Survey Nurse Q3 
Survey Nurse Q4 
Survey Nurse Q5 
Survey Nurse Q6 
Survey Nurse Q6 
Survey MD Q1 
Survey MD Q2 
Survey MD Q3 
Survey MD Q4 
Survey MD Q5 
Survey MD Q6 
Survey 1st Scorer Q1 
Survey 1st Scorer Q2 
Survey 1st Scorer Q3 
Survey 1st Scorer Q4 
Survey 1st Scorer Q5 
Survey 1st Scorer Q6 
Survey 2nd Scorer Q1 
Survey 2nd Scorer Q2 
Survey 2nd Scorer Q3 
Survey 2nd Scorer Q4 
Survey 2nd Scorer Q5 
Survey 2nd Scorer Q6 
 
 
 
Schedule of Events 
Screening for eligibility criteria will be done by the fellow or attending physician during the shift. 
Patients who met inclusion criteria will be approached and consented by the physician prior to 
randomization (consent form attached). 
Verbal assent will be obtained for the children 7-12 years of age. 
 
 
The treatment groups are: 
First group will receive ketamine 3mg/kg (50mg/ml) (max 100mg) plus saline 0.03ml/kg (max 
2ml) through the nose with an applicator. 
Second group will receive midazolam 0.3mg/kg (5mg/ml) (max 10mg) plus fentanyl 1.5mcg/kg 
(50mcg/ml) (max 100mcg) through the nose with an applicator. 
The following activities will occur at the specified study visits: 
 
Screening and Study Activities: 
Medical history obtained

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 18 of 19 
Version #   11/15/18 
 
 
 
 
 
Physical exam 
Vital signs (blood pressure, heart rate, breathing rate, oxygen saturation) 
A numbing cream (lido-epitetracaine topical solution,5ml) will be applied onto the cut for all the 
children in both treatment group as standard of care and we will wait for 20 minutes for the 
cream to show the effect. 
 
20 minutes after the numbing cream: 
 
The nurse will record a full set of vitals and connect the patient to the cardiac and 
respiratory monitor. 
    Patient will receive the drug that is assigned through the nose with an applicator. 
    The nurse will complete the form 
 
 
We will wait for 10 minutes after medication is administered before performing the procedure 
Laceration repair will be performed. 
 
 
Patient’s respiratory rate, blood pressure, heart rate and oxygen saturation will be continuously 
monitored starting before administration of the medications and will be monitored until the 
patient is awake and able to follow commands. 
Patient will be discharged when able to follow commands and drink fluids. 
 
 
All the process will be videotaped for the two consistent scorers. They will be chosen from 
Emergency Medicine Physicians or Pediatricians. In the end of the study, they will  watch the 
videos and evaluate the sedation effects of these medications. The videos will be recorded in a 
memory disc which will be kept in a safe place and will be deleted and discarded in the end of 
the study. This process will be HIPAA compliant, no patient information will be shared with the 
scorers. 
 
 
 
 
Budget Estimate 
1. Personnel : 
Emergency Center Research Staff and Biostatistician- $5,303. 
Mara Branoff, RN BSN is the Emergency Medicine Clinical Research Manager who will be 
provided study oversight and regulatory support. $1,125 inclusive of salary, FICA and fringe is 
requested in support of her effort on the study. 
Clinical research coordinator (TBD) who will recruit study participants and collect data. We 
request $3,144 inclusive of salary, FICA and fringe in support of the research coordinator’s time 
on this study. Effort on project 5%. 
Biostatistical support to provide assistance with randomization, development of the study data 
files, and statistical analysis will cost $1,034. Effort on project 1%. 
2. Research Pharmacy. A total of $3,697 is requested. This request includes costs for research 
pharmacy setup, record administration and study drug management. Medication costs are 
dependent on medication type, doses per patient, patient enrollment, and extra preparation

IRB NUMBER: 2017-363
IRB APPROVAL DATE: 11/21/2018
IRB #2017-363 
Page 19 of 19 
Version #   11/15/18 
 
 
 
 
 
requirements. Calculation assumed all the patients will require maximum dose of the 
medications. 
Preparation of intranasal medication $10/dose $20 x 30 = 600 
Midazolam 5mg/mL, 1 mL vial $0.77/vial $1.54 x 15 = 23.1 
Fentanyl 50mcg/mL, 2 mL vial $0.59/vial $0.59 x 15 = 8.85 
Ketamine 100mg/mL, 5 mL vial $7.64/ vial $7.64 x 15 = 114.6 
3. Equipment: Video camera with tripod: $500 
 
 
Total Budget: $5,303 + $3,697 + $500 = $9,500 
 
 
Funding: 
$5000 from Beaumont Emergency Center Research Fund 
2018 Society for Pediatric Sedation Scholarly Grant Application is done, awaiting results 
for $10,000.